Association study between killer immunoglobulin-like receptor polymorphisms and susceptibility to COVID-19 disease: a systematic review and meta-analysis.

COVID-19 KIR NK cells SARS-CoV-2

Journal

Immunologic research
ISSN: 1559-0755
Titre abrégé: Immunol Res
Pays: United States
ID NLM: 8611087

Informations de publication

Date de publication:
24 Oct 2023
Historique:
received: 13 04 2023
accepted: 12 10 2023
medline: 24 10 2023
pubmed: 24 10 2023
entrez: 24 10 2023
Statut: aheadofprint

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a known virus that leads to a respiratory disease called coronavirus disease 19 (COVID-19). Natural killer (NK) cells, as members of innate immunity, possess crucial roles in restricting viral infections, including COVID-19. Their functions and development depend on receiving signals through various receptors, of which killer cell immunoglobulin-like receptors (KIRs) belong to the most effective ones. Different studies investigated the association between KIR gene content and susceptibility to COVID-19. Since previous studies have yielded contradictory results, we designed this meta-analysis study to draw comprehensive conclusions about COVID-19 risk and KIR gene association. According to PRISMA guidelines, a systematic search was performed in the electronic databases to find all studies investigating KIR gene contents in COVID-19 patients before March 2023. Any association between KIR genes and COVID-19 risk was determined by calculating pooled odds ratio (OR) and 95% confidence interval (CI). After applying the inclusion and exclusion criteria, 1673 COVID-19 patients and 1526 healthy controls from eight studies were included in this meta-analysis. As the main results, we observed a positive association between the 2DL3 (OR = 1.48, 95% CI = 1.17-1.88, P < 0.001) and susceptibility to COVID-19 and a negative association between the 2DP1 and the risk for COVID-19 (OR = 0.48, 95% CI = 0.23-0.99, P = 0.049). This meta-analysis demonstrated that KIR2DL3, as a member of iKIRs, might be associated with an increased risk of COVID-19 disease.

Identifiants

DOI: 10.1007/s12026-023-09428-7 PMID: 37874432
pubmed: 37874432
doi: 10.1007/s12026-023-09428-7
pii: 10.1007/s12026-023-09428-7
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397 .
doi: 10.23750/abm.v91i1.9397 pubmed: 32191675 pmcid: 7569573
Muhareb R, Giacaman R. Tracking COVID-19 responsibly. Lancet. 2020. https://doi.org/10.1016/s0140-6736(20)30693-0 .
doi: 10.1016/s0140-6736(20)30693-0 pubmed: 32224300 pmcid: 7194718
Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3):e7423. https://doi.org/10.7759/cureus.7423 .
doi: 10.7759/cureus.7423 pubmed: 32337143 pmcid: 7182166
Payne S. Family Coronaviridae. Viruses. 2017;149–58. https://doi.org/10.1016/B978-0-12-803109-4.00017-9 .
Kannan S, Shaik Syed Ali P, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019) - recent trends. Eur Rev Med Pharmacol Sci. 2020;24(4):2006–11. https://doi.org/10.26355/eurrev_202002_20378 .
doi: 10.26355/eurrev_202002_20378 pubmed: 32141569
Lotfi R, Kalmarzi RN, Roghani SA. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunol Res. 2021;69(3):213–24.
doi: 10.1007/s12026-021-09198-0 pubmed: 33928531 pmcid: 8084416
Mohammed RN, Tamjidifar R, Rahman HS, Adili A, Ghoreishizadeh S, Saeedi H, et al. A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19). Cell Commun Signal. 2022;20(1):79. https://doi.org/10.1186/s12964-022-00856-w .
doi: 10.1186/s12964-022-00856-w pubmed: 35655192 pmcid: 9162381
Hosseini A, Hashemi V, Shomali N, Asghari F, Gharibi T, Akbari M, et al. Innate and adaptive immune responses against coronavirus. Biomed Pharmacother. 2020;132:110859. https://doi.org/10.1016/j.biopha.2020.110859 .
doi: 10.1016/j.biopha.2020.110859 pubmed: 33120236 pmcid: 7580677
Agrati C, Carsetti R, Bordoni V, Sacchi A, Quintarelli C, Locatelli F, et al. The immune response as a double-edged sword: the lesson learnt during the COVID-19 pandemic. Immunology. 2022;167(3):287–302. https://doi.org/10.1111/imm.13564 .
doi: 10.1111/imm.13564 pubmed: 35971810
Saad N, Moussa S. Immune response to COVID-19 infection: a double-edged sword. Immunol Med. 2021;44(3):187–96. https://doi.org/10.1080/25785826.2020.1870305 .
doi: 10.1080/25785826.2020.1870305 pubmed: 33444511
Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382–93. https://doi.org/10.1038/s41577-021-00542-x .
doi: 10.1038/s41577-021-00542-x pubmed: 33875867 pmcid: 8054133
Alhumaid S, Al Mutair A, Alali J, Al Dossary N, Albattat SH, Al HajjiMohammed SM, et al. Efficacy and safety of tixagevimab/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): a systematic review and meta-analysis. Diseases. 2022;10(4) https://doi.org/10.3390/diseases10040118 .
Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021:10. https://doi.org/10.7554/eLife.66125 .
Vlaar APJ, de Bruin S, Busch M, Timmermans S, van Zeggeren IE, Koning R, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;2(12):e764–e73. https://doi.org/10.1016/s2665-9913(20)30341-6 .
doi: 10.1016/s2665-9913(20)30341-6 pubmed: 33015643 pmcid: 7521913
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196–206. https://doi.org/10.1016/s2213-2600(20)30511-7 .
doi: 10.1016/s2213-2600(20)30511-7 pubmed: 33189161
Di Vito C, Calcaterra F, Coianiz N, Terzoli S, Voza A, Mikulak J, et al. Natural killer cells in SARS-CoV-2 infection: pathophysiology and therapeutic implications. Front Immunol. 2022;13:888248. https://doi.org/10.3389/fimmu.2022.888248 .
doi: 10.3389/fimmu.2022.888248 pubmed: 35844604 pmcid: 9279859
Mikulak J, Bruni E, Oriolo F, Di Vito C, Mavilio D. Hepatic natural killer cells: organ-specific sentinels of liver immune homeostasis and physiopathology. Front Immunol. 2019;10:946. https://doi.org/10.3389/fimmu.2019.00946 .
doi: 10.3389/fimmu.2019.00946 pubmed: 31114585 pmcid: 6502999
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5):503–10.
doi: 10.1038/ni1582 pubmed: 18425107
Dębska-Zielkowska J, Moszkowska G, Zieliński M, Zielińska H, Dukat-Mazurek A, Trzonkowski P, Stefańska K. KIR receptors as key regulators of nk cells activity in health and disease. Cells. 2021;10(7).  https://doi.org/10.3390/cells10071777 .
Sun PD. Structure and function of natural-killer-cell receptors. Immunol Res. 2003;27:539–48.
doi: 10.1385/IR:27:2-3:539 pubmed: 12857997
Rizzo S, Schiuma G, Beltrami S, Gentili V, Rizzo R, Bortolotti D. Role of KIR receptor in NK regulation during viral infections. Immuno. 2021;1(3):305–31.
doi: 10.3390/immuno1030021
Béziat V, Hilton HG, Norman PJ, Traherne JA. Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology. Immunology. 2017;150(3):248–64.
doi: 10.1111/imm.12684 pubmed: 27779741
Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019;10:1179. https://doi.org/10.3389/fimmu.2019.01179 .
doi: 10.3389/fimmu.2019.01179 pubmed: 31231370 pmcid: 6558367
Lee HR, Baek KH. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review). Oncol Rep. 2019;41(5):2625–35. https://doi.org/10.3892/or.2019.7059 .
doi: 10.3892/or.2019.7059 pubmed: 30896812
Cronk JM, Fafoutis E, Brown MG. Licensing natural killers for antiviral immunity. Pathogens. 2021;10(7).  https://doi.org/10.3390/pathogens10070908 .
Boudreau JE, Hsu KC. Natural killer cell education and the response to infection and cancer therapy: stay tuned. Trends Immunol. 2018;39(3):222–39. https://doi.org/10.1016/j.it.2017.12.001 .
doi: 10.1016/j.it.2017.12.001 pubmed: 29397297 pmcid: 6013060
Rascle P, Woolley G, Jost S, Manickam C, Reeves RK. NK cell education: physiological and pathological influences. Front Immunol. 2023;14:1087155. https://doi.org/10.3389/fimmu.2023.1087155 .
doi: 10.3389/fimmu.2023.1087155 pubmed: 36742337 pmcid: 9896005
Paul S, Lal G. The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017;8:1124. https://doi.org/10.3389/fimmu.2017.01124 .
doi: 10.3389/fimmu.2017.01124 pubmed: 28955340 pmcid: 5601256
Shan Z, Huang J, Liao Q, Huang K, Wang M, Xu R, et al. Association of killer cell immunoglobulin-like receptors with spontaneous clearance of hepatitis C virus in the Chinese population. Transfusion. 2018;58(4):1028–35. https://doi.org/10.1111/trf.14527 .
doi: 10.1111/trf.14527 pubmed: 29446443
Ligotti ME, Aiello A, Accardi G, Calabrò A, Ciaccio M, Colomba C, et al. Distribution of KIR genes and their HLA ligands in different viral infectious diseases: frequency study in Sicilian population. Int J Mol Sci. 2022;23(24):15466.
doi: 10.3390/ijms232415466 pubmed: 36555106 pmcid: 9779783
Jackson E, Zhang CX, Kiani Z, Lisovsky I, Tallon B, Del Corpo A, et al. HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric killer immunoglobulin-like receptor (KIR) B motifs; contribution of KIR B motif encoded genes to NK cell responsiveness. PLoS One. 2017;12(9):e0185160. https://doi.org/10.1371/journal.pone.0185160 .
doi: 10.1371/journal.pone.0185160 pubmed: 28938026 pmcid: 5609756
Bernal E, Gimeno L, Alcaraz MJ, Quadeer AA, Moreno M, Martínez-Sánchez MV, et al. Activating killer-cell immunoglobulin-like receptors are associated with the severity of coronavirus disease 2019. J Infect Dis. 2021;224(2):229–40. https://doi.org/10.1093/infdis/jiab228 .
doi: 10.1093/infdis/jiab228 pubmed: 33928374
Littera R, Chessa L, Deidda S, Angioni G, Campagna M, Lai S, et al. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. PLoS One. 2021;16(8):e0255608. https://doi.org/10.1371/journal.pone.0255608 .
doi: 10.1371/journal.pone.0255608 pubmed: 34352002 pmcid: 8341547
Lesan V, Bewarder M, Metz C, Becker A, Mang S, Regitz E, et al. Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019. Intensive Care Med Exp. 2021;9(1):45. https://doi.org/10.1186/s40635-021-00409-4 .
doi: 10.1186/s40635-021-00409-4 pubmed: 34476598 pmcid: 8412971
Hajeer A, Jawdat D, Massadeh S, Aljawini N, Abedalthagafi MS, Arabi YM, Alaamery M. Association of KIR gene polymorphisms with COVID-19 disease. Clin Immunol. 2022;234:108911. https://doi.org/10.1016/j.clim.2021.108911 .
doi: 10.1016/j.clim.2021.108911 pubmed: 34929414
Maruthamuthu S, Rajalingam K, Kaur N, Morvan MG, Soto J, Lee N, et al. Individualized constellation of killer cell immunoglobulin-like receptors and cognate HLA class I ligands that controls natural killer cell antiviral immunity predisposes COVID-19. Front Genet. 2022;13:845474. https://doi.org/10.3389/fgene.2022.845474 .
doi: 10.3389/fgene.2022.845474 pubmed: 35273641 pmcid: 8902362
Hu S, Shao Z, Ni W, Sun P, Qiao J, Wan H, et al. The KIR2DL2/HLA-C1C1 Gene pairing is associated with an increased risk of SARS-CoV-2 infection. Front Immunol. 2022;13:919110. https://doi.org/10.3389/fimmu.2022.919110 .
doi: 10.3389/fimmu.2022.919110 pubmed: 35874712 pmcid: 9301464
Alomar S, Alkhuriji A, Alkhulaifi FM, Mansour L, Al-Jurayyan A, Aldossari GS, et al. Relationship between KIR genotypes and HLA-ligands with SARS-CoV-2 infection in the Saudi population. J King Saud Univ Sci. 2023;35(1):102416. https://doi.org/10.1016/j.jksus.2022.102416 .
doi: 10.1016/j.jksus.2022.102416 pubmed: 36338940
Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(3):315–25. https://doi.org/10.1111/j.1365-2567.2010.03398.x .
doi: 10.1111/j.1365-2567.2010.03398.x pubmed: 21214544 pmcid: 3044898
Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227–58.
doi: 10.1146/annurev-immunol-020711-075005 pubmed: 23516982
Quatrini L, Della Chiesa M, Sivori S, Mingari MC, Pende D, Moretta L. Human NK cells, their receptors and function. Eur J Immunol. 2021;51(7):1566–79. https://doi.org/10.1002/eji.202049028 .
doi: 10.1002/eji.202049028 pubmed: 33899224 pmcid: 9292411
Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011;89(2):216–24. https://doi.org/10.1038/icb.2010.78 .
doi: 10.1038/icb.2010.78 pubmed: 20567250

Auteurs

Saeed Hosseini Teshnizi (SH)

Promotion Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Sara Mirzazadeh (S)

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, PO Box: 71345-1798, Shiraz, Iran.

Niloofar Mashhadi (N)

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, PO Box: 71345-1798, Shiraz, Iran.

Seppo Meri (S)

Department of Bacteriology and Immunology and the Translational Immunology Research Program (TRIMM), The University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland.

Dieter Kabelitz (D)

Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig, Holstein Campus Kiel, 24105, Kiel, Germany.

Kurosh Kalantar (K)

Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, PO Box: 71345-1798, Shiraz, Iran. Kalantark@sums.ac.ir.
Department of Bacteriology and Immunology and the Translational Immunology Research Program (TRIMM), The University of Helsinki and HUSLAB, Helsinki University Hospital, Helsinki, Finland. Kalantark@sums.ac.ir.
Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Kalantark@sums.ac.ir.
ORCID: 0000-0002-9160-9449

Classifications MeSH